Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Activation of GPR40 attenuates neuroinflammation and improves neurological function via PAK4/CREB/KDM6B pathway in an experimental GMH rat model

Fig. 4

Intranasal administration of GW9508 improved short-term neurological outcomes 3 days after GMH. GMH caused neurological deficits were evaluated by negative geotaxis tests (a, b) and righting reflex (c), compared with the sham group. Medium dose group of GW9508 significantly improved neurological function in the first 3 days after GMH. *p < 0.05 vs sham, @p < 0.05 vs vehicle, one-way ANOVA, Tukey test, n = 6. Mean ± SD

Back to article page